Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

65 -- Cell and Recombinant Based Pandemic Influenza Vaccine

Solicitation Number: ORDC-VB-05-04
Agency: Department of Health and Human Services
Office: Office of the Secretary
Location: Assistant Secretary for Preparedness and Response
  • Print
:
ORDC-VB-05-04
:
Award Notice
:
May 4, 2006
:
HHSO100200600010C to HHSO100200600014C
:
169,462,231 to 298,594,057
:
HHSO100200600010C, MedImmune, Gaithersburg, MD, $169,462,231; HHSO100200600011C, GlaxoSmithKline, Phila., PA, $274,752,168; HHSO100200600012C, Novartis (formerly Chiron), Emeryville, CA, $220,507,491; HHSO100200600013C, DynPort Vaccine, Frederick, MD, $242,582,756 (Incrementally funded at $40,971,895 through 7/31/2007); HHSO100200600014C, Solvay Pharmaceuticals, Marietta, Georgia, $298,594,057
:
Added: March 17, 2005 Modified: May 5, 2006Track Changes
No Description Provided
:
Department of Health and Human Services, Office of the Secretary, Office of Public Health Emergency Preparedness, Office of Research and Development Coordination 200 Independence Avenue, SW Room 636G, Washington, DC, 20201
:
Schuyler Eldridge, Contracting Officer, Phone 202-205-4679, Fax 202-205-6092, Email schuyler.eldridge@hhs.gov - David Beck, Chief Contracting Officer, Phone 202-205-5639, Fax 202-205-6092, Email david.beck@hhs.gov